title: Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
abstract: Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.
authors.affiliation: Ospedale San Donato USL8, Medical Oncology, Department of Oncology, 52100 Arezzo, Italy. sergio.bracarda@usl8.toscana.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Bracarda
authors.forename: Enzo Maria
authors.initials: EM
authors.lastname: Ruggeri
authors.forename: Marcello
authors.initials: M
authors.lastname: Monti
authors.forename: Marco
authors.initials: M
authors.lastname: Merlano
authors.forename: Alessandro
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Francesco
authors.initials: F
authors.lastname: Ferraù
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000517:prevention & control; D019468:Disease Management; D005076:Exanthema / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007636:Keratoacanthoma / Q000209:etiology / Q000517:prevention & control; D007680:Kidney Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011537:Pruritus / Q000209:etiology / Q000517:prevention & control; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib